(Q36968183)

17 August 2017

1 reference

title

Erlotinib in non-small-cell lung cancer (English)

1 reference

17 August 2017

1

Cesare Gridelli

1 reference

17 August 2017

Antonio Rossi

2

1 reference

17 August 2017

Paolo Maione

3

1 reference

17 August 2017

Giuseppe Colantuoni

4

1 reference

17 August 2017

Filomena Del Gaizo

5

1 reference

17 August 2017

Carmine Ferrara

6

1 reference

17 August 2017

Dario Nicolella

7

1 reference

17 August 2017

Ciro Guerriero

8

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

15

1 reference

17 August 2017

page(s)

2579-2592

1 reference

Estimating the world cancer burden: Globocan 2000.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

HER1/EGFR targeting: refining the strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

The HER receptor family: a rich target for therapeutic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Who should be sent for genetic testing in hereditary colorectal cancer syndromes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.15.2579

10.1517/14656566.8.15.2579

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference